Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SPN041
MIFTS: 54

Spinal Cord Disease

Categories: Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Spinal Cord Disease

About this section

MalaCards integrated aliases for Spinal Cord Disease:

Name: Spinal Cord Disease 12 15 17
Spinal Cord Diseases 54 42 44 70
Myelopathy 12 15
Bone Marrow Diseases 70

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:319
ICD9CM 34 336.9
MeSH 44 D013118
NCIt 50 C97110
SNOMED-CT 67 48522003
UMLS 70 C0005956 C0037928
Sources

Summaries for Spinal Cord Disease

About this section
MedlinePlus : 42 Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. It is protected by your vertebrae, which are the bone disks that make up your spine. If you have an accident that damages the vertebrae or other parts of the spine, this can also injure the spinal cord. Other spinal cord problems include Tumors Infections such as meningitis and polio Inflammatory diseases Autoimmune diseases Degenerative diseases such as amyotrophic lateral sclerosis and spinal muscular atrophy Symptoms vary but might include pain, numbness, loss of sensation and muscle weakness. These symptoms can occur around the spinal cord, and also in other areas such as your arms and legs. Treatments often include medicines and surgery.

MalaCards based summary : Spinal Cord Disease, also known as spinal cord diseases, is related to vascular myelopathy and myelitis, and has symptoms including seizures, tremor and myoclonus. An important gene associated with Spinal Cord Disease is BTD (Biotinidase), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Human cytomegalovirus infection. The drugs Sevoflurane and Meloxicam have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, bone and prostate, and related phenotypes are behavior/neurological and hematopoietic system

Wikipedia : 73 The spinal cord is a long, thin, tubular structure made up of nervous tissue, which extends from the... more...

Sources

Related Diseases for Spinal Cord Disease

About this section

Diseases related to Spinal Cord Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1223)
# Related Disease Score Top Affiliating Genes
1 vascular myelopathy 32.8 MOG DPYSL5 AQP4
2 myelitis 31.8 MOG MBP IL6 IFNB1 ICOSLG DPYSL5
3 central nervous system disease 31.6 MOG MIR142 MBP IL6 ICOSLG H2AC18
4 adult t-cell leukemia 31.4 CNTN2 CD4 CCR6
5 spinal cord injury 31.1 IL6 GFAP GDNF AQP4
6 hydrocephalus 31.0 MTOR MBP GFAP AQP4
7 acquired immunodeficiency syndrome 31.0 MBP IL6 CD4 CCR6
8 sarcoidosis 1 30.9 ICOSLG CD8A CD4 CCR6
9 spondylitis 30.9 IL6 ICOSLG CCR6
10 hemangioma 30.9 TSC2 TSC1 MTOR IL6
11 t-cell adult acute lymphocytic leukemia 30.9 HBZ CNTN2 CD8A CD4 CCR6
12 neurosarcoidosis 30.8 MOG CD8A CD4 AQP4
13 optic neuritis 30.8 MOG MBP IL6 GFAP DPYSL5 AQP4
14 neuritis 30.8 MOG MBP IL6 GFAP GDNF DPYSL5
15 dermatitis 30.7 IL6 CD8A CD4 CCR6 BTD
16 herpes zoster 30.7 ICOSLG CD8A CD4 CCR6
17 chickenpox 30.7 IL6 IFNB1 ICOSLG CD8A CD4 CCR6
18 leukemia, acute lymphoblastic 30.6 MIR142 ICOSLG HBZ H2AC18 CD8A CD4
19 benign ependymoma 30.6 TSC2 TSC1 MTOR GFAP
20 spondyloarthropathy 1 30.6 IL6 ICOSLG CCR6
21 allergic encephalomyelitis 30.6 MOG MBP
22 optic papillitis 30.6 MOG CD4 AQP4
23 exanthem 30.6 MTOR IL6 ICOSLG H2AC18 CD8A CD4
24 systemic lupus erythematosus 30.6 MTOR MIR142 IL6 IFNB1 ICOSLG H2AC18
25 polyradiculopathy 30.5 MBP ICOSLG CD4
26 pancytopenia 30.5 IL6 H2AC18 CD8A CD4
27 acute transverse myelitis 30.5 IL6 AQP4
28 acute disseminated encephalomyelitis 30.5 MOG MBP IFNB1 CCR6 AQP4
29 transverse myelitis 30.5 MOG MBP IL6 ICOSLG CCR6 AQP4
30 respiratory failure 30.5 IL6 H2AC18 CD8A CD4 CCR6
31 primary progressive multiple sclerosis 30.5 MOG MBP IFNB1
32 retinal vasculitis 30.5 IFNB1 CD4 CCR6
33 arachnoiditis 30.4 CD4 AQP4
34 chiari malformation 30.4 MBP GFAP
35 chronic inflammatory demyelinating polyradiculoneuropathy 30.4 MBP IFNB1 ICOSLG
36 syphilis 30.4 IL6 CD8A CD4 CCR6
37 encephalitis 30.4 MOG IL6 IFNB1 GFAP AQP4
38 primary biliary cholangitis 30.4 ICOSLG H2AC18 CD8A CD4 CCR6
39 acute cystitis 30.4 IL6 H2AC18 CD4 CCR6
40 obstructive hydrocephalus 30.4 TSC1 MTOR GFAP AQP4
41 spinal disease 30.4 MIR142 IL6 ICOSLG H2AC18 GFAP CCR6
42 optic nerve disease 30.3 MOG MBP IL6 IFNB1 ICOSLG GFAP
43 demyelinating disease 30.3 MOG MIR142 MBP IL6 IFNB1 ICOSLG
44 connective tissue disease 30.3 MIR142 IL6 ICOSLG H2AC18 CD8A CD4
45 neuromyelitis optica 30.3 MOG MBP IL6 GFAP AQP4
46 autoimmune disease 30.3 MOG MBP IL6 IFNB1 ICOSLG CCR6
47 substance abuse 30.3 MOG IL6 H2AC18 CD4 CCR6
48 traumatic brain injury 30.2 MBP IL6 GFAP AQP4
49 leprosy 3 30.2 IL6 CD8A CD4 CCR6
50 relapsing-remitting multiple sclerosis 30.2 MOG MBP IL6 IFNB1 CCR6 AQP4

Comorbidity relations with Spinal Cord Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Hypertension, Essential
Osteoporosis Paraplegia
Prostate Cancer Spinal Stenosis

Graphical network of the top 20 diseases related to Spinal Cord Disease:



Diseases related to Spinal Cord Disease
Sources

Symptoms & Phenotypes for Spinal Cord Disease

About this section

UMLS symptoms related to Spinal Cord Disease:


seizures; tremor; myoclonus; back pain; headache; syncope; hemiplegia; pain; chronic pain; sciatica; vertigo/dizziness; sleeplessness; hyperexplexia

MGI Mouse Phenotypes related to Spinal Cord Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 AQP4 BTD CNTN2 DPYSL5 GDNF GFAP
2 hematopoietic system MP:0005397 9.93 AQP4 CCR6 CD4 CD8A GDNF HBZ
3 nervous system MP:0003631 9.83 AQP4 CCR6 CD4 CD8A CNTN2 DPYSL5
4 renal/urinary system MP:0005367 9.23 AQP4 BTD CD8A GDNF IL6 MTOR
Sources

Drugs & Therapeutics for Spinal Cord Disease

About this section

Drugs for Spinal Cord Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 190)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
2
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
3
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
4
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
5
Zoledronic Acid Approved Phase 4 118072-93-8 68740
6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
7 Cyclooxygenase Inhibitors Phase 4
8 Cyclooxygenase 2 Inhibitors Phase 4
9 Antirheumatic Agents Phase 4
10 Anti-Inflammatory Agents, Non-Steroidal Phase 4
11 Neurotransmitter Agents Phase 4
12 Anticonvulsants Phase 4
13 Psychotropic Drugs Phase 4
14 Anti-Anxiety Agents Phase 4
15 Diphosphonates Phase 4
16 Vitamins Phase 4
17 Calciferol Phase 4
18 Solifenacin succinate Phase 4 242478-38-2
19 Muscarinic Antagonists Phase 4
20 Parasympatholytics Phase 4
21 Cholinergic Agents Phase 4
22 Cholinergic Antagonists Phase 4
23 Immunoglobulins Phase 4
24 Antibodies Phase 4
25 Immunoglobulins, Intravenous Phase 4
26 Immunologic Factors Phase 4
27 gamma-Globulins Phase 4
28 Rho(D) Immune Globulin Phase 4
29
sodium fluoride Approved Phase 3 7681-49-4
30
Zidovudine Approved Phase 2, Phase 3 30516-87-1 35370
31
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
32
Riluzole Approved, Investigational Phase 3 1744-22-5 5070
33
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
34
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
35
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
36
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 3 52485-79-7 644073 40400
37
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
38
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
39
Mogamulizumab Approved, Investigational Phase 3 1159266-37-1
40
Denosumab Approved Phase 3 615258-40-7
41
Etoposide Approved Phase 3 33419-42-0 36462
42
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
43
Daunorubicin Approved Phase 3 20830-81-3 30323
44
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
45
Ifosfamide Approved Phase 3 3778-73-2 3690
46
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
47
Mannitol Approved, Investigational Phase 3 69-65-8 6251 453
48
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
49
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
50
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676

Interventional clinical trials:

(show top 50) (show all 245)
# Name Status NCT ID Phase Drugs
1 Anesthesia Induction With Propofol or Sevoflurane in Patients Undergoing Fiberoptic Intubation for Cervical Myelopathy: Effects on Heamodynamics Unknown status NCT01052337 Phase 4 anaesthetics: sevofluorane
2 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
3 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
4 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
5 A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid and Circulating Tumor Cell Measurements in Patients With HER2-negative Metastatic Breast Cancer Without Bone Metastasis Completed NCT01129336 Phase 4 Zoledronic acid;Standard Therapy
6 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
7 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
8 Open Labelled Study of Pregabalin in the Treatment of Neuropathic Pain in Cervical Myeloradiculopathy (Pregabalin and Radicular Pain Study (PARPS)) Completed NCT01061697 Phase 4 Pregabalin
9 A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
10 Arthroplasty Versus Fusion in Anterior Cervical Surgery: Prospective Study of the Impact on the Adjacent Level Completed NCT00554528 Phase 4
11 HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens Completed NCT03226119 Phase 4
12 Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study Not yet recruiting NCT02480634 Phase 4 Zoledronic acid
13 A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy Terminated NCT01561755 Phase 4 Intravenous Immunoglobulin;Placebo
14 A Phase 4, Randomized, Double-blind, Placebo-controlled, Cross-over Clinical Trial of a Single Shot of Intrathecal Ziconotide for the Treatment of Chronic, Medically Refractory Pain From Painful Peripheral Neuropathy or Myelopathy Withdrawn NCT01992562 Phase 4 Ziconotide;placebo
15 Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
16 Phase 3 Study Evaluating Fentanyl Transmucosal in the Prevention of Pain Induced by Mobilization During Radiotherapy in Patients With Bone Metastasis Unknown status NCT02426697 Phase 3 fentanyl transmucosal;Placebo
17 18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques Unknown status NCT00882609 Phase 3
18 Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases: a Randomized Phase II/III Trial Unknown status NCT01429493 Phase 2, Phase 3
19 Treatment of AIDS Vacuolar Myelopathy With Methionine Completed NCT00032695 Phase 3 methionine
20 Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial Completed NCT00272480 Phase 2, Phase 3 Zidovudine/lamivudine;Placebos
21 Efficacy of Riluzole in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. A Randomized, Double-Blind, Placebo-controlled Multi-Center Study Completed NCT01257828 Phase 3 riluzole;Placebo medication
22 The CSM Trial: A Multicenter Study Comparing Ventral to Dorsal Surgery for Cervical Spondylotic Myelopathy Completed NCT00506558 Phase 3
23 The HAM Ciclosporin Study : an Observational Trial of Therapy in Early or Progressing HAM/TSP Completed NCT00773292 Phase 2, Phase 3 ciclosporin
24 An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain) Completed NCT01202227 Phase 3 pregabalin
25 NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain Completed NCT01476774 Phase 3 Buprenorphine Transdermal System;Buprenorphine Transdermal System
26 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer Completed NCT00321464 Phase 3 Zoledronic Acid
27 A Randomized Phase III Double-Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases Completed NCT01248585 Phase 3 Dexamethasone;Placebo
28 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Completed NCT00330759 Phase 3 Zoledronic Acid
29 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer Completed NCT00321620 Phase 3 zoledronic acid
30 A Randomized, Double-blind, Multi-centre Study to Evaluate the Fficacy and Safety of Zometa as a Treatment in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma Completed NCT00219258 Phase 3 Zoledronic acid
31 Investigation of Optimal Radiotherapy Regimen and Type of Irradiation in Treatment of Painful Bone Metastasis Completed NCT00610272 Phase 3
32 A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms Completed NCT02163226 Phase 2, Phase 3
33 Dexamethasone for the Prevention of a Pain Flare After Palliative Radiotherapy for Painful Bone Metastases: a Multi-center Double-blind Placebo-controlled Randomized Study Completed NCT01669499 Phase 3 Dexamethasone acetate;Placebo
34 A Phase 3 Multinational, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Ph+ CML Patients in Early Chronic Phase Completed NCT01511289 Phase 3 Imatinib;Radotinib
35 Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer Completed NCT01419717 Phase 3 Denosumab
36 Phase III Study of Palliative Radiotherapy for Bone Metastases Comparing Single to Multiple Fractions. Completed NCT00858741 Phase 3
37 An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma Completed NCT00950911 Phase 3 amg 162
38 Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-four-week Zometa in Breast Cancer Patients With Bone Metastases Completed NCT00524849 Phase 2, Phase 3 Zoledronic acid
39 A Prospective, Randomized, Multi-Center, Post-Approval Clinical Trial Evaluating the Long-Term (7 Year) Safety and Effectiveness of the PCM® Cervical Disc Completed NCT01905930 Phase 3
40 Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS Completed NCT03127514 Phase 2, Phase 3 AMX0035
41 A Prospective, Randomized, Controlled Clinical Investigation Comparing PCM® Cervical Disc Arthroplasty to Anterior Cervical Discectomy and Fusion: 2 Year Results From the US IDE Clinical Trial Completed NCT00578812 Phase 3
42 The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury Completed NCT01555983 Phase 2, Phase 3 Vaporization of Cannabis
43 A Prospective Randomized Double-blinded Clinical Trial About the Efficacy of Oral Limaprost Administration Following Surgery for Cervical Myelopathy Recruiting NCT02125981 Phase 3 Limaprost;Placebo
44 A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Clinical Efficacy and Safety of QL1206 and Xgeva® in Patients With Bone Metastases From Solid Tumors Recruiting NCT04550949 Phase 3 QL1206;Xgeva
45 Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients With Bone Metastases Recruiting NCT04307914 Phase 3
46 A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM) Active, not recruiting NCT03191526 Phase 3 KW-0761 0.3 mg/kg IV;Placebo (saline)
47 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
48 A Multi-center, Randomized, Double-blind, Parallel Controlled Phase â…¢ Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Anti RANKL Monoclonal Antibody Injection (MW032) and Denosumab (Xgeva®) in Subjects With Bone Metastases From Solid Tumors Active, not recruiting NCT04812509 Phase 3 MW032;Xgeva
49 The Effect of Gentamicin Intravesical Installations on Decreasing Urinary Tract Infections in Patients With Neurogenic Bladder After Spinal Cord Injury: A Clinical Trial Active, not recruiting NCT03503513 Phase 2, Phase 3 Gentamicin Sulfate;Saline
50 Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy Not yet recruiting NCT04631471 Phase 3 Ibudilast;Matching placebo

Search NIH Clinical Center for Spinal Cord Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carboplatin

Cochrane evidence based reviews: spinal cord diseases

Sources

Genetic Tests for Spinal Cord Disease

About this section
Sources

Anatomical Context for Spinal Cord Disease

About this section

MalaCards organs/tissues related to Spinal Cord Disease:

40
Spinal Cord, Bone, Prostate, Bone Marrow, Medulla Oblongata, Brain, Myeloid
Sources

Publications for Spinal Cord Disease

About this section

Articles related to Spinal Cord Disease:

(show top 50) (show all 547)
# Title Authors PMID Year
1
Is it safe and effective to correct congenital scoliosis associated with multiple intraspinal anomalies without preliminary neurosurgical intervention? 42
33725816 2021
2
Predictors associated with neurological recovery after anterior decompression with fusion for degenerative cervical myelopathy. 42
33740929 2021
3
Increased signal intensity of spinal cord on T2W magnetic resonance imaging for cervical spondylotic myelopathy patients: Risk factors and prognosis (a STROBE-compliant article). 42
33285685 2020
4
Effect of distortion corrections on the tractography quality in spinal cord diffusion-weighted imaging. 61
33475180 2021
5
Multiple stenting using anchoring technique with balloon guiding catheter for common carotid artery dissection after aortic arch replacement: A case report. 61
33756166 2021
6
Application of ultrasound during electrode implantation for sacral neuromodulation in patients with neurogenic bladder secondary to spinal cord disease: a retrospective study. 61
33743121 2021
7
A Systematic review and meta-analysis of sensate versus non-sensate flaps for the prevention of pressure ulcer recurrence among individuals with spinal cord disease. 61
33727678 2021
8
[Inflammatory spinal cord diseases and transverse myelitis]. 61
33570678 2021
9
[Differential diagnostics of autoimmune inflammatory spinal cord diseases]. 61
33765163 2021
10
Late-onset Leber's hereditary optic neuropathy presenting with longitudinally extensive myelitis harbouring the m.14484T>C mutation: Extending the genotype-phenotype spectrum. 61
33360266 2021
11
Peripheral Neuropathy in the Lower Limbs of Individuals With Spinal Cord Injury or Disease: A Retrospective Study. 61
32618751 2021
12
The Physiology Associated With "Bed Rest" and Inactivity and How It May Relate to the Veterinary Patient With Spinal Cord Injury and Physical Rehabilitation. 61
33778033 2021
13
First Documented Cases of Canine Neuroangiostrongyliasis Due to Angiostrongylus cantonensis in Hawaii. 61
33260206 2021
14
Neuromodulation for Restoration of Urinary and Bowel Control. 61
33318367 2020
15
Faster RCNN-based detection of cervical spinal cord injury and disc degeneration. 61
32797664 2020
16
Follow-up consultations through telerehabilitation for wheelchair recipients with paraplegia in a developing country: a case report. 61
32632104 2020
17
Sarcoidosis and the Nervous System. 61
32487903 2020
18
Flourine-18 fluorodeoxyglucose positron emission tomography imaging exhibits increased SUVmax at the level of the spinal intumescence in normal dogs. 61
31916651 2020
19
Accuracy of transcranial magnetic stimulation and a Bayesian latent class model for diagnosis of spinal cord dysfunction in horses. 61
32030834 2020
20
Multi-Omic Approach to Identify Phenotypic Modifiers Underlying Cerebral Demyelination in X-Linked Adrenoleukodystrophy. 61
32671069 2020
21
Intramedullary spinal cord lesions in an immunocompromised host due to Mycobacterium haemophilum. 61
32226763 2020
22
Spinal Cord Microglia in Health and Disease. 61
32477594 2020
23
Genetics of Degenerative Cervical Myelopathy: A Systematic Review and Meta-Analysis of Candidate Gene Studies. 61
31968564 2020
24
International Comparison of Vocational Rehabilitation for Persons With Spinal Cord Injury: Systems, Practices, and Barriers. 61
32095065 2020
25
A Spine-Specific Phased Array for Transvertebral Ultrasound Therapy: Design and Simulation. 61
30998457 2020
26
Optimization of Microemulgel for Tizanidine Hydrochloride. 61
30854978 2020
27
Central Sensitivity Is Associated with Poor Recovery of Pain: Prediction, Cluster, and Decision Tree Analyses. 61
33178373 2020
28
Retrospective analysis of diagnoses and outcomes of 45 cats with micturition disorders presenting as urinary incontinence. 61
31859391 2020
29
Degenerative Cervical Myelopathy in Higher-Aged Patients: How Do They Benefit from Surgery? 61
31888031 2019
30
Transcutaneous transmission of photobiomodulation light to the spinal canal of dog as measured from cadaver dogs using a multi-channel intra-spinal probe. 61
30879228 2019
31
Ultrasound-Induced Blood-Spinal Cord Barrier Opening in Rabbits. 61
31248640 2019
32
Energy balance following diets of varying fat content: metabolic dysregulation in a rodent model of spinal cord contusion. 61
31456327 2019
33
Comparison of cerebrospinal fluid parameters from the cerebellomedullary and lumbar cisterns in 54 dogs. 61
31391608 2019
34
Giant intradural extramedullary spinal ependymoma, a rare arachnoiditis-mimicking condition: case report and literature review. 61
31213094 2019
35
Neurological disorders in HIV in Africa: a review. 61
31656479 2019
36
Intervertebral T3-T4 Disc Extrusions in Two German Shepherd Dogs. 61
30870609 2019
37
Aetiology of Myelopathy in a Tertiary Hospital of Bangladesh. 61
31086136 2019
38
Clinical Manifestations and Surgical Management of Spinal Lesions in Patients With Mucopolysaccharidosis: A Report of 52 Cases. 61
30660225 2019
39
Disease progression in women with X-linked adrenoleukodystrophy is slow. 61
30732635 2019
40
Necessity of performing voiding cystourethrography for children with unilateral multicystic dysplastic kidney. 61
30255447 2019
41
Age-related Changes in the Global DNA Methylation Profile of Oligodendrocyte Progenitor Cells Derived from Rat Spinal Cords. 61
30868493 2019
42
[Intraoperative video-angiography in surgery for spinal intramedullary cavernous malformations: first experience of its application at the Burdenko Neurosurgical Center]. 61
32031168 2019
43
The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration. 61
30252065 2019
44
Prevalence of Bowel Symptoms in Patients Infected with Human T-Lymphotropic type 1 Virus. 61
31778419 2019
45
Delayed-Onset Paraplegia Due to Spinal Cord Infarction After Repeated Tumor Excision Surgeries of the Thoracic Spine. 61
30371920 2019
46
A Systematic Review of the Utility of the Hoffmann Sign for the Diagnosis of Degenerative Cervical Myelopathy. 61
29668564 2018
47
Mining healthcare data for markers of the multiple sclerosis prodrome. 61
30121490 2018
48
Flaccid paralysis in neuromyelitis optica: An atypical presentation with possible involvement of the peripheral nervous system. 61
30056360 2018
49
Unexpected prion phenotypes in experimentally transfused animals: predictive models for humans? 61
30080439 2018
50
In Vivo Spinal Distribution of Cy5.5 Fluorescent Dye after Injection via the Lateral Ventricle and Cisterna Magna in Rat Model. 61
29660974 2018
Sources

Variations for Spinal Cord Disease

About this section
Sources

Expression for Spinal Cord Disease

About this section
Search GEO for disease gene expression data for Spinal Cord Disease.
Sources

Pathways for Spinal Cord Disease

About this section

Pathways related to Spinal Cord Disease according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Cellular Senescence (REACTOME) 65
Show member pathways
 13.01 TSC2 TSC1 MTOR IL6 IFNB1 H2AC18
2
Human cytomegalovirus infection 36
Show member pathways
 12.71 TSC2 TSC1 MTOR IL6 IFNB1 CD4
3
Allograft rejection 1 36
Show member pathways
 12.7 IL6 ICOSLG GDNF CD8A CD4
4
Herpes simplex virus 1 infection 36
12.62 TSC2 TSC1 MTOR IL6 IFNB1
5
JAK-STAT signaling pathway 36
Show member pathways
 12.27 MTOR IL6 IFNB1 GFAP
6
Cellular senescence (KEGG) 36
11.95 TSC2 TSC1 MTOR IL6
7
Cell adhesion molecules 36
11.88 ICOSLG CNTN2 CD8A CD4
8
Yersinia infection 36
11.76 IL6 IFNB1 CD8A CD4
9
Interferon Pathway 63
11.73 MTOR IL6 IFNB1
10
TP53 Regulates Metabolic Genes 65
11.68 TSC2 TSC1 MTOR
11
Innate Lymphoid Cell Differentiation Pathways 64
11.63 CD8A CD4 CCR6
12
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.61 MOG GFAP GDNF
13
IgA-Producing B Cells in the Intestine 64
11.51 IL6 ICOSLG CCR6
14
mTOR signaling pathway (Pathway Interaction Database) 1
11.45 TSC2 TSC1 MTOR
15
Wnt Signaling Pathway Netpath 1
11.38 TSC2 TSC1 MTOR
16
LKB1 signaling events 1
11.17 TSC2 TSC1 MTOR
17
Dendritic Cells Developmental Lineage Pathway 64
11.13 IL6 IFNB1 CD8A CD4
18
Spinal Cord Injury 1
11.1 MBP IL6 GFAP GDNF AQP4
19
BDNF-TrkB Signaling 1
10.95 TSC2 TSC1 MTOR
20
Cytokines and Inflammatory Response 1
10.79 IL6 IFNB1 CD4
Sources

GO Terms for Spinal Cord Disease

About this section

Cellular components related to Spinal Cord Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 astrocyte end-foot GO:0097450 9.16 GFAP AQP4
2 external side of plasma membrane GO:0009897 9.1 MOG ICOSLG CD8A CD4 CCR6 AQP4
3 TSC1-TSC2 complex GO:0033596 8.96 TSC2 TSC1

Biological processes related to Spinal Cord Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.77 MBP IL6 CD8A CD4 CCR6
2 adaptive immune response GO:0002250 9.65 TSC1 IFNB1 ICOSLG CD8A CD4
3 positive regulation of neuroinflammatory response GO:0150078 9.43 MIR142 IL6
4 anoikis GO:0043276 9.4 TSC2 MTOR
5 humoral immune response GO:0006959 9.33 IL6 IFNB1 CCR6
6 negative regulation of cell size GO:0045792 9.32 TSC1 MTOR
7 T cell activation GO:0042110 9.13 ICOSLG CD8A CD4
8 positive regulation of glial cell proliferation GO:0060252 8.8 MTOR IL6 GFAP
Sources

Sources for Spinal Cord Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....